# NCT06312670 (NCT06312670)

> Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06312670
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pedro Barata, MD, MSc
- Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma
- Interventions: EPI-7386; Enzalutamide; Androgen Deprivation Therapy (ADT)
- Enrollment: 13
- Primary outcome: Biochemical response rate
- Primary outcome: PSA progesterone-free survival (PFS)
- Primary outcome: Radiographic PFS (rPFS)
- Primary outcome: ORR (confirmed)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 9
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06312670

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06312670", "email": "<work email>"}; the inbox owner confirms by the emailed link.